Skip to content

Middle Meningeal Artery (MMA) Embolization Compared to Traditional Surgical Strategies to Treat Chronic Subdural Hematomas (cSDH)

Pilot Study to Evaluate Safety of and Efficacy of Middle Meningeal Artery (MMA) Embolization Compared to Traditional Surgical Strategies to Treat Chronic Subdural Hematomas (cSDH)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04095819
Enrollment
50
Registered
2019-09-19
Start date
2019-06-19
Completion date
2022-04-19
Last updated
2019-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Subdural Hematoma

Brief summary

Chronic Subdural Hematoma (cSDH) is a common hematologic problem particularly in older patients. The purpose of this study is to evaluate the safety and efficacy of middle meningeal artery (MMA) embolization compared to traditional surgical strategies for patients presenting with chronic subdural hematoma (cSDH). Although MMA embolization is minimally-invasive procedure that is routinely used for the treatment of tumors or vascular formations (1), this study investigates the use of an established procedure for a new disease state.

Detailed description

The purpose of the research study is to evaluate the safety and efficacy of a new, less-invasive procedure to treat chronic subdural hematoma (cSDH). A subdural hematoma occurs when blood collects on the brain's surface beneath the skull. Subdural hematomas can be life-threatening. They usually result from a head injury. This study will compare the new procedure to conventional surgical treatment of chronic subdural hematoma (cSDH). The new procedure is called middle meningeal artery embolization (MMA). Current or conventional treatment of chronic subdural hematoma (cSDH) involves surgery (burr hole drainage and craniotomy) to access and remove the cause of the bleeding that is causing the subdural hematoma. The new procedure, MMA embolization, involves guiding a catheter that is inserted into a blood vessel to the area of the brain that is supplying blood to the subdural hematoma. Particles or a special type of glue will be released to stop the bleeding that is causing the subdural hematoma. This technique has been used to treat other brain conditions, for example, (to treat tumors or malformation of blood vessels).

Interventions

PROCEDUREMiddle Meningeal Artery procedure

Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma

Drainage of Subdural Hematoma using Craniotomy or Burr Hole

Sponsors

Atlantic Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 or older * Participant or Surrogate must be English speaking * Subjects must have a diagnosis of chronic or acute-on subdural hematoma based on brain imaging, as documented by an * One or more symptoms attributable to chronic SDH including headache cognitive impairment, gait instability, seizure, or mild focal neurologic deficit. * In opinion of Investigator or the subject's referring physician, the subject has failed conservative management.

Exclusion criteria

* The Subdural hematoma is causing mass effect significant enough to cause marked or progressive neurologic impairment * Any requirement for urgent surgical evacuation is necessary * Life expectancy is less than 6 months in the opinion of the subject's primary physician * Markedly tortuous vasculature precluding safe endovascular access, as assessed on angiogram * Acute subdural hematomas * Health insurance doesn't cover MMA embolization or performing Surgeon and follow up visits are considered out of network. * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change in size of SDH6 monthsChanges in size of SDH will be recorded in maximum diameter within 6 months.

Secondary

MeasureTime frameDescription
Change in Neurological status6 monthsChanges in Neurological status after the procedure and through study completion

Countries

United States

Contacts

Primary ContactBenitez
rbenitez@ansdocs.com973-285-7800
Backup ContactElena Lobur, RN
elena.lobur@atlantichealth.org908-522-2045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026